HMNC BRAIN HEALTH | a disruptive clinical stage biopharma company pioneering precision psychiatry

Um den vollen visuellen und funktionalen Umfang dieser Website genießen zu können, aktivieren sie bitte Javascript in ihrem Browser.

Publications

Jan '26

Efficacy and safety of BH-200, a selective vasopressin V1b receptor antagonist, in the treatment of genetically defined subgroups of patients with major depressive disorder (MDD)

American College of Neuropsychopharmacology Annual Meeting,
January 2026

Oct '23

Novel Genetic In Vitro Diagnostic Test to Predict Efficacy of BH-200, a V1b Antagonist, in Major Depressive Disorder - A Phase II Randomized Controlled Trial

ISCTM Autumn Conference with ECNP,
October 2023

Innovation

HMNC Brain Health develops game-changing therapies for mental health disorders

Vision &
Mission

Develop personalized precision psychiatry treatments with AI, setting new standards in psychiatric care.

Excellence

HMNC Brain Health uses state-of-the-art scientific methods to develop future oriented therapies for mental health disorders - based on deep insight into the genomics in mental health